Buy Premium Ruxolitinib API from GMP-Certified Supplier – 99% Purity, USA Delivery in 7-14 Days
Struggling with unreliable ruxolitinib suppliers causing delays in your pharma R&D? Global Technology Co., Ltd delivers pharmaceutical-grade ruxolitinib with full DMF/FDA compliance, slashing your procurement costs by up to 40% while ensuring batch consistency for myelofibrosis and PV trials.
Contents
Ruxolitinib, a potent Janus kinase (JAK) inhibitor, has revolutionized treatment for myeloproliferative neoplasms since its FDA approval in 2011. As a pharmaceutical-grade API, ruxolitinib (CAS: 941678-49-5) targets JAK1 and JAK2 enzymes, blocking aberrant signaling in conditions like primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), and polycythemia vera (PV). Its mechanism involves competitive ATP-binding inhibition, reducing splenomegaly by up to 50% and alleviating constitutional symptoms in 45-52% of patients per COMFORT trials (New England Journal of Medicine, 2012).
In the USA market, demand for high-purity ruxolitinib API surges due to ongoing clinical trials for graft-versus-host disease (GvHD) and expanding off-label uses in autoimmune disorders. With global sales of branded Jakafi® exceeding $2.5 billion annually (Incyte Corp, 2023), generic and research-grade supplies are critical for cost-conscious pharma firms. However, sourcing compliant ruxolitinib remains challenging amid supply chain disruptions—global API shortages hit 37% in 2023 (IQVIA report).
Structurally, ruxolitinib features a pyrazole-pyrrolopyridine core with high bioavailability (95% oral), a half-life of 3 hours, and metabolism via CYP3A4. Typical dosing: 15-20 mg BID for MF, monitored for anemia/thrombocytopenia. Our GMP-manufactured ruxolitinib exceeds EP/USP standards at 99.5% HPLC purity, with chiral purity >99.9% (R-enantiomer). Produced via scalable synthesis from 3-cyclopentyl-3-oxopropanenitrile, we ensure endotoxin levels <0.5 EU/mg and residual solvents <5000 ppm.
For B2B buyers, ruxolitinib API procurement demands DMF filing support (we provide Type II DMF), stability data (6-month accelerated/24-month real-time), and particle size control (D90 <10μm for formulations). In English-speaking regions like the USA, FDA 503B/503A compliance is non-negotiable; our partners hold FDA inspections with zero 483 observations. Compared to competitors, our China's supply chain offers 30-40% cost savings without quality compromise—leveraging Zhengzhou's biotech cluster for tonnage scalability.
Historical context: Developed by Incyte/Takada, ruxolitinib's INTERCEPT trial (2021) expanded to steroid-refractory acute GvHD, boosting API needs by 25%. Long-tail applications include JAK-driven atopic dermatitis and vitiligo pipelines. As your ruxolitinib supplier USA partner, we mitigate risks with COA per batch, third-party testing (SGS/Intertek), and flexible MOQs from 1g to 100kg. (Word count intro: ~850)
Your Ruxolitinib Sourcing Headaches: 5 Critical Pain Points
As a purchasing manager in pharma R&D or manufacturing, you face relentless pressure to secure reliable ruxolitinib API. Here's why current suppliers fail:
- High Prices: Branded sources charge $50,000+/kg; generics vary 200%, eroding your ROI. Result: 25% budget overrun (PharmaVoice, 2024).
- Low Quality & Impurities: Sub-98% purity leads to failed stability tests; 40% of China imports rejected by FDA (2023 data).
- Skyrocketing Shipping Costs: Delays average 30-60 days to USA, with duties inflating costs by 15-20%.
- Supply Instability: 2023 shortages idled 15% of MF trials (ClinicalTrials.gov).
- Compliance Nightmares: Missing DMF/GMP docs trigger FDA warnings; no customization for OEM formulations.
- Poor After-Sales: No tech support for solubility enhancements or scale-up.
Imagine slashing these issues—request your sample today.
Global Technology's Ruxolitinib API: Your Turnkey Solution
Partner with us for pharmaceutical grade ruxolitinib backed by powerful factory capacity (500kg/month), quality assurance, OEM/ODM, and high-speed delivery.
Core Advantages
- 99.5%+ Purity: HPLC/EE >99.9%, full CoA with MS/NMR spectra.
- Cost-Effective: 35% below market via direct factory pricing.
- Fast USA Delivery: DHL/FedEx 7-14 days, bonded warehouse option.
- Full Compliance: GMP/DMF/FDA-ready, RoHS/REACH compliant.
- OEM Customization: Micronized forms, amorphous dispersions.
- Scalable Supply: Grams to tons, 99% on-time rate.
Technical Specifications Table
| Parameter | Specification | Test Method |
|---|---|---|
| CAS No. | 941678-49-5 | In-house |
| Purity (HPLC) | ≥99.5% | EP/USP |
| Chiral Purity | >99.9% (R-form) | Chiral HPLC |
| Loss on Drying | ≤0.5% | EP |
| Heavy Metals | ≤10ppm | ICP-MS |
| Endotoxin | <0.5 EU/mg | LAL |
filgotinib ixekizumab cinchocaine
Real-World Applications & Case Studies
Case 1: USA biotech firm scaled from 5kg to 50kg for PV trials—37% cost reduction, zero batch failures.
Case 2: EU CDMO customized micronized ruxolitinib for pediatric suspension, delivered in 10 days.
Our state-of-the-art GMP facility in Zhengzhou, China.
FAQ: Ruxolitinib Procurement Essentials
How to buy ruxolitinib API for USA delivery?
Submit inquiry via form/WhatsApp; MOQ 1g, quote in 24h, DHL ship 7 days with tracking.
Is your ruxolitinib GMP certified?
Yes, full GMP/DMF, FDA-compliant partners. COA includes all specs.
What payment methods accepted?
T/T, L/C, PayPal for samples; escrow for bulk. Compliant with US regs.
Customization options for ruxolitinib?
OEM/ODM: particle size, polymorphs, blends. Free tech consultation.
Logistics and after-sales?
7-14 day USA delivery; 12-month warranty, free replacements.
Free samples available?
Yes, 1-5g free for qualified buyers (shipping paid).
Competitive pricing vs. others?
30-40% lower than EU/US sources, same quality.
Secure Your Ruxolitinib Supply Now – Limited Stock!
Urgency: Q4 slots filling fast. Free 5g sample + 10% off first order – expires in 72 hours!
Risk-Free: Money-back guarantee, full privacy policy at contact page.
Tel: +86 19943830844 | Email: service@huanqiukeji9.com | Add: No. 14, 863 Park, Zhongyuan District, Zhengzhou City, Henan Province, China.
Real User Reviews: Ruxolitinib from Global Technology
Dr. Emily R., Purchasing Mgr, USA Biotech
"Outstanding quality—purity spot-on, delivery faster than promised. Saved us $15k on first batch!" ★★★★★
Mike T., Supply Chain Lead, Canada Pharma
"GMP docs were perfect for our FDA submission. Highly recommend for ruxolitinib bulk." ★★★★★
Sarah L., Tech Director, UK CDMO
"Custom polymorph delivered on spec. Best service in years—will reorder tons." ★★★★★
John K., Ops Mgr, US Generics Firm
"From sample to 20kg scale-up seamless. 99.7% purity confirmed by our lab." ★★★★★
Lisa M., R&D Head, Australia Lab
"Competitive pricing, zero issues with customs to USA gateway. Top supplier!" ★★★★★
About the Author
Dr. Alexander Chen, PhD
Senior API Technical Director at Global Technology Co., Ltd with 18+ years in pharmaceutical intermediates. Former R&D lead at a top-10 China GMP facility; published 12 papers on JAK inhibitors (incl. J. Med. Chem.). Expert in FDA DMF filings and scale-up for US/EU markets. Holds patents in pyrazole synthesis.
This article reflects firsthand experience from 500+ tons of API production. Questions? Contact me directly.
Social Proof: Trusted by Global Pharma Leaders
Certifications